Document Detail


Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
MedLine Citation:
PMID:  19423296     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Panayiotopoulos syndrome (PS) represents the second commonest benign partial epilepsy of childhood. This study evaluated the effects of levetiracetam (LEV) in three children with this syndrome. All three children (aged 8, 12 and 10 years) had episodic autonomic symptoms for 4, 6 and 2 years, respectively. Symptoms duration varied between a few minutes and 5-7 days, reflecting an autonomic status epilepticus. Children previously controlled on valproate (VPA) but with recurring seizures, were given LEV (1000-2000 mg/day) initially as add-on therapy, and after as monotherapy. All three children received LEV monotherapy and remained seizure-free after 3, 3 and 2 years of treatment, respectively. One child, after 2 years seizure free, stopped LEV treatment. Now, he is asymptomatic for 2 years. LEV has shown efficacy on autonomic seizure control in three patients with PS where VPA was ineffective.
Authors:
Carmen García; Guillermo Rubio
Related Documents :
18810626 - Brief report: decoding representations: how children with autism understand drawings.
18163576 - Synthesis, characterization, and dna adsorption studies of ampholytic model conetworks ...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2009-05-06
Journal Detail:
Title:  Epilepsy research     Volume:  85     ISSN:  1872-6844     ISO Abbreviation:  Epilepsy Res.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-21     Completed Date:  2009-09-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8703089     Medline TA:  Epilepsy Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  318-20     Citation Subset:  IM    
Affiliation:
Neurology Service, Hospital Jerez, Cádiz, Spain. cgarciaguijo@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticonvulsants / adverse effects,  therapeutic use*
Child
Drug Therapy, Combination
Electroencephalography
Epilepsies, Partial / drug therapy*
Female
Humans
Magnetic Resonance Imaging
Male
Piracetam / adverse effects,  analogs & derivatives*,  therapeutic use
Status Epilepticus / drug therapy
Syndrome
Valproic Acid / therapeutic use
Chemical
Reg. No./Substance:
0/Anticonvulsants; 33996-58-6/etiracetam; 7491-74-9/Piracetam; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of a tracheostomy scoring system to guide airway management after major head and neck su...
Next Document:  Delusions, illusions and hallucinations in epilepsy: 1. Elementary phenomena.